Abstract |
We analysed the treatment outcome of localized extranodal NK/T cell lymphoma initially treated with CEOP-B chemotherapy based on the primary site of involvement (nasal cavity vs. upper aerodigestive tract) and treatment modality ( chemotherapy vs. chemotherapy followed by radiotherapy. Forty-three patients newly diagnosed as extranodal NK/T cell lymphoma were analysed: 29 cases from nasal cavity/nasopharynx and 14 from upper aerodigestive tract. Twenty-six patients were treated with chemotherapy alone, while adjuvant radiotherapy was given to 17 patients. Overall response rate to front-line CEOP-B chemotherapy was 67.4% (29/43) and the complete remission (CR) rate was 44.2% (19/43). Median overall and disease-free survival was 26.87 months [95% confidence interval (CI) = 8.71 - 45.03] and 15.27 months (95% CI = 2.92 - 27.62). The responders (CR or partial response) to initial CEOP-B chemotherapy showed longer overall survival than non-responders (P = 0.0026). Local relapse was observed to be higher in the chemotherapy alone group compared to the chemoradiotherapy group. Adjuvant radiotherapy failed to improve survival; thus, the median disease-free survival of the chemotherapy and chemoradiotherapy groups was not different (P = 0.9101). There may be a tendency for better overall survival in group of upper aerodigestive tract lymphoma than the nasal cavity/nasopharynx group (P = 0.0643). However, front-line CEOP-B chemotherapy has a limited role and adjuvant radiotherapy failed to improve survival in localized extranodal NK/T cell lymphoma.
|
Authors | Seok Jin Kim, Byung Soo Kim, Chul Won Choi, Hee Yun Seo, Hye Ryoung Seol, Hwa Jung Sung, In Sun Kim, Chul Yong Kim, Kwang Yoon Jung, Jun Suk Kim |
Journal | Leukemia & lymphoma
(Leuk Lymphoma)
Vol. 47
Issue 7
Pg. 1265-73
(Jul 2006)
ISSN: 1042-8194 [Print] United States |
PMID | 16923556
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Bleomycin
- Epirubicin
- Vincristine
- Cyclophosphamide
- Prednisone
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Bleomycin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Disease Progression
- Disease-Free Survival
- Epirubicin
(administration & dosage)
- Female
- Humans
- Killer Cells, Natural
(cytology)
- Lymphoma, T-Cell
(drug therapy, pathology)
- Male
- Middle Aged
- Prednisone
(administration & dosage)
- Proportional Hazards Models
- Recurrence
- Remission Induction
- Time Factors
- Treatment Outcome
- Vincristine
(administration & dosage)
|